AVBP News & Events

"Our two ongoing pivotal firmonertinib trials in uncommon EGFR-mutant non-small cell lung cancer continue to advance, with topline monotherapy data for frontline EGFR exon 20 insertion mutations expected in mid-2026 and our global Phase 3 pivotal ALPACCA study continuing to enroll patients globally," said Bing Yao, CEO of ArriVent. "At American Association for Cancer Research, we presented preclinical data highlighting the unique structural features of firmonertinib that improve binding and enhance activity against EGFR mutant proteins, further strengthening confidence in the broad activity of firmonertinib in EGFR-mutant NSCLC."

ArriVent BioPharma announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravalent antibody-drug conjugate with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.